ʻO Retatrutide kahi peptide synthetic hou i hoʻolālā ʻia e hoʻāla i ʻekolu mau mea loaʻa nui e pili ana i ka homeostasis glucose a me ke koena o ka ikehu: glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) a me glucagon-like peptide-1 receptor (GLP- 1R) (Finan et al., 2023, The New England Journal of Medicine).Ma ka huli ʻana i kēia mau mea loaʻa, hoʻohālikelike ʻo retatrutide i nā hopena o kā lākou endogenous ligands, glucagon, GIP a me GLP-1, ʻo ia nā hormones e hoʻoponopono ai i ka metabolism glucose a me ke kaumaha o ke kino i nā ʻāpana like ʻole, e like me ka pancreas, ate, lolo, adipose tissue a me ka ʻōpū. tract (Drucker, 2023, Nature).
ʻAʻole like me nā ligand endogenous, he pōkole ka hapalua o ke ola, hoʻohaʻahaʻa wikiwiki ʻia e ka dipeptidyl peptidase-4 (DPP-4) enzyme a me nā hopena ʻaoʻao makemake ʻole, e like me ka hypoglycemia a me ka nausea (Drucker, 2023, Nature), ua hana ʻia ka retatrutide e lanakila ai i kēia mau mea. palena.ʻO Retatrutide kahi peptide fusion i haku ʻia me kahi kaʻina glucagon i hoʻololi ʻia i hoʻopili ʻia i kahi kaʻina GLP-1 i hoʻololi ʻia ma o kahi kaʻina GIP (Finan et al., 2023, The New England Journal of Medicine).Hoʻololi nā hoʻololi i ka hoʻololi ʻana i ka waikawa amino a me ka holoi ʻana e hoʻomaikaʻi ai i ka kūpaʻa, ka ikaika a me ke koho ʻana o ka peptide no nā ʻae ʻekolu (Finan et al., 2023, The New England Journal of Medicine).
Ua hōʻike ʻo Retatrutide i nā waiwai pharmacological kupaianaha a me ka maikaʻi therapeutic i ka momona a me ka maʻi diabetes type 2 i nā haʻawina preclinical a me ke kauka.I nā ʻano holoholona o ka momona a me ka maʻi diabetes, ua hōʻike ʻo retatrutide i nā hopena maikaʻi loa i ka hoʻohaʻahaʻa ʻana i ke kiʻekiʻe o ka glucose koko, hoʻoulu i ka huna ʻana o ka insulin, kaohi ʻana i ka huna ʻana o ka glucagon, hoʻopaneʻe i ka hoʻokuʻu ʻana o ka ʻōpū, hōʻemi i ka ʻai ʻana i ka meaʻai a me ke kaumaha o ke kino i hoʻohālikelike ʻia i nā agonists hoʻokahi a ʻelua paha o nā mea loaʻa ʻekolu (Gault et. al., 2023, Diabetes, Obesity and Metabolism; Coskun et al., 2023a, Molecular Metabolism).Ua hoʻomaikaʻi hou ʻo Retatrutide i ka ʻike lipid, ka hana ate, ka mumū a me nā ʻāpana cardiovascular i kēia mau holoholona (Gault et al., 2023, Diabetes, Obesity and Metabolism; Coskun et al., 2023a, Molecular Metabolism).
I loko o nā hoʻokolohua lapaʻau kanaka, ua hōʻike pū ʻia ka retatrutide i nā hopena hoʻohiki i nā mea maʻi obese a me ka maʻi diabetes.Ua ʻae maikaʻi ʻia ʻo Retatrutide a hōʻike i nā hopena pili i ka hopena i ka hoʻohaʻahaʻa ʻana i ke kiʻekiʻe o ka glucose koko, ka hoʻoulu ʻana i ka huna ʻana o ka insulin, ke kāohi ʻana i ka huna ʻana o ka glucagon a me ka hoʻohaʻahaʻa ʻana i ka makemake i kahi haʻawina 1 e pili ana i nā limahana olakino a me nā mea maʻi me ka maʻi diabetes type 2 (Coskun et al., 2023b, Diabetes Care ).Loaʻa ka Retatrutide a hiki i ka 17.5% mean hoʻemi kaumaha ma 24 mau pule i hoʻohālikelike ʻia me kahi placebo ma kahi haʻawina 2 e pili ana i nā maʻi me ka momona a me ke kaumaha.Ua hui pū ʻia kēia pohō kaumaha me ka hoʻomaikaʻi ʻana i ka mana glycemic, profile lipid, hana ate a me ka maikaʻi o ke ola (Lilly's phase 2 retatrutide hualoaʻa i paʻi ʻia ma The New England Journal of Medicine e hōʻike ana i ka molekele noiʻi i loaʻa i ka 17.5% mean weight reduction ma 24 mau pule i loko. nā mākua me ka momona a me ke kaumaha., 2023).Loaʻa iā Retatrutide kahi ʻōlelo palekana maikaʻi me ka ʻole o nā hanana koʻikoʻi koʻikoʻi a i ʻole hōʻike ʻia nā ʻāpana hypoglycemia.
Kiʻi 1. ʻO Retatrutide (LY3437943) ke kāohi i ka glycated hemoglobin A1c (HbA1c) waiwai (A) a me ke kaumaha kino (B) i ka manawa.
(Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, Haupt A, Benson CT, Hernandez-Illas M, D'Alessio DA, Milicevic Z. LY3437943, he moʻolelo triple GIP, GLP-1, a glucagon receptor agonist i loko o ka poʻe me ka maʻi maʻi type 2: he māhele 1b, multicentre, double-blind, placebo-controlled, randomized, multiple-ascending dose trial. Lancet. 2022 Nov 26;400(10366):1869-1881.)
Ke hoʻomohala ʻia nei ʻo Retatrutide e Eli Lilly a me Company ma ke ʻano he moho lāʻau hou no ka momona a me ka maʻi diabetes type 2.Hōʻike ia i kahi ala hou no ka huli ʻana i nā mea loaʻa he nui e pili ana i ka metabolism glucose a me ke koena o ka ikehu me hoʻokahi mole.Ua hōʻike ʻo Retatrutide i ka maikaʻi maikaʻi loa i nā hoʻohālike holoholona a me nā hoʻāʻo kanaka me nā ʻaoʻao palekana a me ka hoʻomanawanui.Pono nā haʻawina hou aʻe e hōʻoia i kāna mau pōmaikaʻi lōʻihi a me nā pilikia e hiki mai ana i nā heluna nui a ʻokoʻa.Hiki ke hāʻawi aku ʻo Retatrutide i kahi koho hou no nā poʻe maʻi e hakakā nei me ka momona a me ka maʻi diabetes a makemake i nā lāʻau lapaʻau ʻoi aku ka maikaʻi.
He mea hana polypeptide mākou ma Kina, me nā makahiki he nui o ka ʻike makua i ka hana polypeptide.ʻO Hangzhou Taijia Biotech Co., Ltd. he mea hana ʻoihana polypeptide raw material, hiki ke hāʻawi i nā ʻumi kaukani o ka polypeptide raw material a hiki ke hana ʻia e like me nā pono.He maikaʻi ka maikaʻi o nā huahana polypeptide, a hiki i ka maʻemaʻe ke hiki i ka 98%, iʻikeʻia e nā mea hoʻohana ma ka honua holoʻokoʻa.Welcome e nīnau iā mākou.
